From: Migraine pathogenesis and state of pharmacological treatment options
Drug | Mechanism of action | Stage of development |
---|---|---|
Acute attack | ||
Telcagepant (MK-0974) | CGRP receptor antagonist | Phase III- complete |
BI 44370 | CGRP receptor antagonist | Phase II |
COL-144 | 5-HT1F receptor agonists | Phase II |
SB-705498 | TRPV1 receptor antagonists | Phase II |
BGG492 | AMPA receptor antagonist | Phase II |
Tezampanel (LY-293558) | AMPA and kainate receptor antagonist | Phase II |
LY466195 | GLUK5 kainate receptor antagonists | Phase II |
NPS 1776 | Anticonvulsant | Phase II |
BGC20-1531 | Prostanoid EP4 receptor antagonist | Phase II |
NXN-188 | nNOS inhibition and 5-HT1B/D agonist | Phase II |
Preventives | ||
Ramelteon | Melatonin MT1 and MT2 receptor agonist | Phase IV |
Botulinum Toxin type A | Unknown | Phase III |
Tonabersat | Gap junction/CSD inhibitor | Phase II- failed in migraine without aura |
ADX10059 | mGluR5 Modulator | Phase II |
Perampanel (E2007) | AMPA receptor antagonist | Phase II |
GW274150 | iNOS | Phase II- failed |
Carisbamate (RWJ-333369) | Anticonvulsant | Phase II- failed |